Acute Airway Vascular Smooth Muscle Effects of Inhaled Budesonide - Full Text View

Purpose

Glucocorticosteroids recently have been shown to have non-genomic actions that are plasma membrane-mediated and do not require gene transcription and translation. One of these non-genomic effects is the inhibition of adrenergic agonist transport into airway vascular smooth muscle cells with an increase of adrenergic agonist concentrations at adrenergic receptor sites and enhance the physiological effects of endogenous adrenergic agonists (e.g. locally released norepinephrine from noradrenergic neurons) or exogenous adrenergic agonists (e.g. inhaled beta-adrenergic agonists).

Condition	Intervention
Asthma	Drug: Budesonide 360ug Drug: Budesonide 720ug Drug: Budesonide 1440ug Drug: Budesonide720ug 4 times Drug: Placebo


Study Type:	Interventional
Study Design:	Allocation: Randomized Endpoint Classification: Pharmacokinetics/Dynamics Study Intervention Model: Single Group Assignment Masking: Double Blind (Subject, Investigator) Primary Purpose: Basic Science
Official Title:	Acute Airway Vascular Smooth Muscle Effects of Inhaled Budesonide

Resource links provided by NLM:

Drug Information available for: Budesonide

U.S. FDA Resources

Further study details as provided by University of Miami:

Primary Outcome Measures:

Airway Blood Flow (Qaw) [ Time Frame: participants will be followed for 6 hours after budesonide dose ] [ Designated as safety issue: No ]
Qaw will be measured before and up to 6 hours after a single inhaled dose of 360ug, 720ug, and 1440ug budesonide or placebo from a DPI, using a double-blinded randomized design on different days.

Secondary Outcome Measures:

Forced Expiratory Volume in 1 Second (FEV1) [ Time Frame: participant will be followed up to 6 hours after budesonide dose ] [ Designated as safety issue: No ]
FEV1 will be measured before and up to 6 hours after a single inhaled dose of 360ug, 720ug, and 1440ug budesonide or placebo from a DPI, using a double-blinded randomized design on different days.


Enrollment:	20
Study Start Date:	July 2008
Study Completion Date:	August 2012
Primary Completion Date:	August 2012 (Final data collection date for primary outcome measure)

Arms	Assigned Interventions
Experimental: budesonide 360ug asthmatic subject received different doses of inhaled budesonide in random other	Drug: Budesonide 360ug A single inhaled dose of 360ug budesonide from a DPI. Other Name: Pulmicort Flexhaler
Experimental: budesonide 720ug asthmatic subject received different doses of inhaled budesonide in random other	Drug: Budesonide 720ug A single inhaled dose of 720ug budesonide from a DPI. Other Name: Pulmicort Flexhaler
Experimental: budesonide 1440ug asthmatic subject received different doses of inhaled budesonide in random other	Drug: Budesonide 1440ug A single dose of 1440ug of the budesonide from DPI. Other Name: Pulmicort Flexhaler
Placebo Comparator: placebo asthmatic subject received inhaled placebo	Drug: Budesonide720ug 4 times 720ug of budesonide will be inhaled by the subjects 4 times, separated by 30 minutes. Other Name: Pulmicort Flexhaler
Experimental: Budesonide720ug 4 times asthmatic subject received 720ug of inhaled budesonide 4 times separated by 30 minutes.	Drug: Placebo A single inhaled dose of placebo from a DPI. Other Name: sugar pill

Detailed Description:

Inhaled glucocorticosteroids typically are not recommended for the treatment of acute asthma attacks. This practice is based on the fact that glucocorticosteroids by themselves do not cause rapid bronchodilation. However, the acute inhibition of adrenergic agonist disposal by the non-genomic action of glucocorticosteroids could lead to bronchial vasoconstriction by locally released norepinephrine thereby decongesting the airway wall, and potentiate the bronchodilator effect of a concomitantly administered beta-adrenergic agonist through the same mechanism. The purpose of this study is to assess the vasoconstrictive effects of single and repetitive high-dose budesonide inhalations in moderate to severe asthmatics who use inhaled glucocorticosteroids regularly. As a secondary endpoint, airway inflammation and airway function will also be measured with the expectation that acute improvements in airflow might be detectable as a result of airway decongestion, notably in subjects with moderately severe asthma who have lower baseline lung function.

Eligibility


Ages Eligible for Study:	18 Years to 65 Years (Adult)
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:

Twenty lifetime nonsmokers moderate or severe asthmatics; FEV1≥50 of predicted on the screening day

Exclusion Criteria:

Women of childbearing potential who do not use accepted birth control measures; pregnant and breast feeding women; Cardiovascular disease and/or use of cardiovascular medication; Subjects with known beta-adrenergic agonist or glucocorticosteroid intolerance; Acute respiratory infection and or acute exacerbation of asthma within four weeks prior to the study; Use of systemic glucocorticosteroids within 4 weeks prior to the study; Daily ICS dose (fluticasone or budesonide) > 500ug; Diabetes mellitus

Contacts and Locations

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01219738

Locations


United States, Florida
Pulmonary Human Research Laboratory, University of Miami, Miller School of Medicine
Miami, Florida, United States, 33136

Sponsors and Collaborators

University of Miami

AstraZeneca

Investigators


Principal Investigator:	Eliana Mendes, MD	University of Miami

More Information

Publications:

Horvath G, Sutto Z, Torbati A, Conner GE, Salathe M, Wanner A. Norepinephrine transport by the extraneuronal monoamine transporter in human bronchial arterial smooth muscle cells. Am J Physiol Lung Cell Mol Physiol. 2003 Oct;285(4):L829-37. Epub 2003 Jun 13.

Horvath G, Lieb T, Conner GE, Salathe M, Wanner A. Steroid sensitivity of norepinephrine uptake by human bronchial arterial and rabbit aortic smooth muscle cells. Am J Respir Cell Mol Biol. 2001 Oct;25(4):500-6.

Mendes ES, Pereira A, Danta I, Duncan RC, Wanner A. Comparative bronchial vasoconstrictive efficacy of inhaled glucocorticosteroids. Eur Respir J. 2003 Jun;21(6):989-93.

Brieva JL, Danta I, Wanner A. Effect of an inhaled glucocorticosteroid on airway mucosal blood flow in mild asthma. Am J Respir Crit Care Med. 2000 Jan;161(1):293-6.

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

Mendes ES, Rebolledo P, Campos M, Wanner A. Immediate antiinflammatory effects of inhaled budesonide in patients with asthma. Ann Am Thorac Soc. 2014 Jun;11(5):706-11. doi: 10.1513/AnnalsATS.201307-220OC.


Responsible Party:	Eliana Mendes, University of Miami
ClinicalTrials.gov Identifier:	NCT01219738 History of Changes
Other Study ID Numbers:	20071068 IRUSBUPF0002
Study First Received:	October 12, 2010
Results First Received:	November 12, 2014
Last Updated:	January 7, 2015
Health Authority:	United States: Institutional Review Board

Keywords provided by University of Miami:


Asthma, airway blood flow, budesonide, glucocorticosteroid.

Additional relevant MeSH terms:


Budesonide Anti-Inflammatory Agents Bronchodilator Agents Autonomic Agents Peripheral Nervous System Agents Physiological Effects of Drugs	Anti-Asthmatic Agents Respiratory System Agents Glucocorticoids Hormones Hormones, Hormone Substitutes, and Hormone Antagonists

ClinicalTrials.gov processed this record on September 23, 2016